| Summary: | Zhigang Wang,1,3 Zheng Wang,1 Zhu Liang,3 Jikuan Liu,3 Weicheng Shi,3 Peiru Bai,3 Xialu Lin,2 Ruth Magaye,2 Jinshun Zhao21Jinan University, Guangzhou, Guangdong, People's Republic of China; 2Public Health Department of Medical School, Zhejiang Provincial Key Laboratory of Pathological and Physiological Technology, Ningbo University, Zhejiang, 3The Affiliated Hospital of Guangdong Medical College, Zhanjiang, Guangdong, People's Republic of ChinaAbstract: The expression and clinical significance of insulin-like growth factor 1 (IGF-1), insulin-like growth factor binding protein 3 (IGFBP-3), and insulin-like growth factor binding protein 7 (IGFBP-7) were investigated in serum and lung cancer tissues from 57 patients with non-small cell lung cancer (NSCLC). Lung cancer tissues at different pathologic stages (27 patients at stages I–II and 30 patients at stages III–IV), normal lung tissues from 17 patients with benign pulmonary disease, and serum samples from both lung cancer and benign pulmonary disease patients were collected during surgery. Enzyme-linked immunosorbent assay and avidin-biotin-peroxidase complex immunohistochemical staining were used to detect IGF-1, IGFBP-3, and IGFBP-7 expression in serum and tissues, respectively. The results show that expression of IGF-1 in lung cancer tissues and serum from NSCLC patients were significantly higher than in the control (P < 0.05). However, expression of IGFBP-3 and IGFBP-7 in cancer tissues and serum from NSCLC patients was significantly lower than in the control (P < 0.05). These results suggest that upregulation of IGF-1 and downregulation of IGFBP-3 and IGFBP-7 may be potential diagnostic biomarkers for NSCLC.Keywords: insulin-like growth factor 1, insulin-like growth factor binding protein 3, insulin-like growth factor binding protein 7, non-small cell lung cancer, diagnostic biomarkers
|
|---|
